Micofenolato De Mofetil Generis

Mycophenolate Mofetil, the active ingredient in Micofenolato De Mofetil Generis, is an antimetabolite immunosuppressant presented as an oral formulation for oral use. It is employed to prevent acute organ transplant rejection, treat lupus nephritis, and manage selected autoimmune diseases in adult and pediatric patients as appropriate.

GNH USA supplies Micofenolato De Mofetil Generis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution.

Mycophenolate Mofetil is used to modulate immune activity in transplant and autoimmune disease contexts. - Prevention of acute organ transplant rejection: reduces the risk of graft loss by suppressing lymphocyte proliferation. - Treatment of lupus nephritis: controls renal inflammation associated with systemic lupus erythematosus. - Management of certain autoimmune diseases: mitigates disease activity in conditions such as vasculitis or dermatomyositis. - Prevention of graft‑versus‑host disease in bone marrow transplantation: limits donor T‑cell activation and tissue damage.

Adverse reactions may occur with Mycophenolate Mofetil therapy.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: frequent loose stools. - Vomiting: occasional emesis. - Abdominal pain: cramping or discomfort. - Headache: transient tension‑type headaches. - Upper respiratory infections: increased susceptibility to colds.

Serious or Rare Side Effects: - Leukopenia or neutropenia: significant drop in white blood cells. - Anemia: reduced red blood cell count. - Severe infections: opportunistic or systemic infections. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Malignancy risk: potential increased risk of certain cancers. - Progressive multifocal leukoencephalopathy: rare viral brain infection.

Patients receiving Mycophenolate Mofetil should be monitored closely for safety. - Monitor blood counts: perform regular CBC to detect leukopenia or anemia. - Assess renal function: adjust dosing in patients with impaired kidney function. - Assess hepatic function: monitor liver enzymes periodically. - Avoid use in uncontrolled infection: risk of worsening infectious disease. - Pregnancy and lactation: discuss potential risks with the prescriber before use. - Store at ambient temperature: keep below 25 °C, retain original packaging, and protect from moisture.

Mycophenolate Mofetil can interact with several medicines.

Major Interactions (Avoid): - Azathioprine: additive bone‑marrow suppression may lead to severe cytopenias. - Live vaccines: increased risk of vaccine‑derived infection.

Moderate Interactions (Monitor Closely): - Antacids containing magnesium or aluminum: may reduce mycophenolate absorption; separate dosing by at least 2 hours. - Cyclosporine or tacrolimus: can increase mycophenolate exposure; monitor drug levels. - Warfarin: may potentiate anticoagulant effect; check INR more frequently.